Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Study of Adebrelimab Combined With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules in the Treatment of Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma That Failed First-line Immunotherapy Combined With Chemotherapy

NCT06339619 is registered in ClinicalTrials.gov with Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University as lead sponsor.

NCT NCT06339619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06339619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Study of Adebrelimab Combined With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules in the Treatment of Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma That Failed First-line Immunotherapy Combined With Chemotherapy
Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase
Phase 2
Overall status
Recruiting
Start date
March 11, 2024
Completion date
September 1, 2028
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic esophageal squamous cell carcinoma